BrightSpring Health (BTSG) Beats Q2 2026 Estimates, Raises Guidance
As seen on the 24/7 Wall St. homepage on July 31, 2026.
BrightSpring crushed expectations with a 13% EPS beat and 5.7% revenue beat, raising full-year guidance on the back of a 28% jump in pharmacy profit per prescription and a 54% surge in home health census from recent acquisitions.
Continue ReadingShow less
BrightSpring Health Services reported Q2 2026 earnings per share of $0.45, clearing the consensus estimate of roughly $0.40 by about 13%. Revenue came in at $3.87 billion, a 5.7% beat versus the $3.66 billion analysts had expected. The company also raised its full-year guidance, signaling that management sees the outperformance as durable rather than a one-quarter anomaly.
Two specific drivers powered the beat. Pharmacy profit per prescription jumped 28%, reflecting either better pricing, mix, or cost discipline within that segment — and home health census surged 54%, a gain the company attributed to recent acquisitions folding new patient volume into its network. Together those two levers show BrightSpring expanding both its core pharmacy economics and its home-based care footprint at the same time.
Disclosure
*$149 for two years (or $1.43 per week) is an introductory promotion for new members only. 62% discount based on the current list price of Stock Advisor of $199/year. Membership will renew at the then-current list price at the end of the membership term. Stock Advisor returns are 930% as compared to the S&P 500 returns of 185% as of April 7, 2026.
The same investor newsletter that told subscribers to buy Amazon in 2002, Netflix in 2004, and Nvidia in 2005 still publishes two new stock picks every month. Over 23 years, Motley Fool's Stock Advisor has more than quadrupled the S&P 500. New members get this month's picks, the Top 10 Rankings, and a 30-day money-back guarantee. Click here to unlock their next top stocks while new members are still being accepted.
Zooming out on the earnings history, the trajectory has been steadily upward: reported EPS has climbed from $0.10 in Q2 2024 to $0.45 in Q2 2026, and BrightSpring has beaten or matched estimates in seven of the nine quarters shown. The consistency of those beats, alongside the raised guidance, is likely what investors will focus on heading into the back half of 2026.